视网膜母细胞瘤中NY-SAR-35基因的表达及临床意义  

Expression of NY-SAR-35 in retinoblastoma and its clinical significance

作　　者：孔旻[1] 林泉[1] 梁皓[1] 蒋林志[1] 严宇清[1] 

机构地区：[1]广西医科大学第一附属医院眼科中心,南宁530021

出　　处：《中国临床新医学》2011年第9期813-816,共4页CHINESE JOURNAL OF NEW CLINICAL MEDICINE

基　　金：广西科技厅青年基金资助项目(编号:桂科青0542052);广西卫生厅自筹经费科研课题(编号:桂卫Z2006049)

摘　　要：目的检测癌-睾丸抗原NY-SAR-35基因在视网膜母细胞瘤(RB)中的表达,探讨其作为RB特异性免疫治疗靶抗原的可能性。方法利用逆转录-聚合酶链反应方法,检测NY-SAR-35基因在15例RB组织、12例非肿瘤病变视网膜和22例其他正常眼部组织(眼睑皮肤12例、眼肌5例、结膜5例)中的表达,随机抽取RT-PCR阳性产物直接进行DNA测序,并将其表达结果与临床相关指标(性别、年龄、病理分型、肿瘤大小、临床分期)进行统计学分析,以探讨这一类肿瘤抗原的临床意义。结果在15例RB组织中,NY-SAR-35基因的表达率为60%(95%CI:35.2%～84.8%);在非肿瘤病变视网膜组织和其他正常组织中,无一例表达NY-SAR-35基因;其表达与临床相关指标(性别、年龄、病理分型、肿瘤大小、临床分期)无关(P>0.05)。结论 NY-SAR-35基因可特异性地表达于RB中,可能成为RB特异性免疫治疗的靶抗原,具有进一步研究开发的前景。Objective To detect the mRNA expression of the cancer testis antigens （NY-SAR-35） in retinoblastoma （RB） and investigate the possibility of applying these antigens as the target antigens for RB specific immunotherapy. Methods With reverse-transcription polymerase chain reaction （ RT-PCR）, the mRNA expression of NY- SAR-35 in 15 cases of RB tissues, 12 cases of nontumorous＇ retina tissues and 22 cases of other ocular region normal tissues （12 cases of blepharo-cutis ,5 cases of musculi oculi and 5 cases of conjunctiva） was detected. Samples selected randomly from PCR positive products of each CT gene were directly sequenced. The results of expression and related clinical parameters （ sex, age, patho-typing, tumorous size, clinical stage） were analyzed with statistic analysis software. Results Among 15 RB tissues, NY-SAR-35 mRNA was detected in 60% （95% CI：35.2% - 84. 8% ）, and NY-SAR-35 mRNA can not be detected in both nontumomus＇ region and other ocular region normal tissues. Conclusion NY-SAR-35 is expressed specifically in RB. So NY-SAR-35 may become special target antigen of immunity treatment. This result is worth further study.

关 键 词：视网膜母细胞瘤 癌-睾丸抗原 肿瘤免疫治疗 

分 类 号：R739.7[医药卫生—肿瘤]